Seeking Alpha

Hyperion Therapeutics (HPTX +34%) trades up today after winning FDA approval for its first drug,...

Hyperion Therapeutics (HPTX +34%) trades up today after winning FDA approval for its first drug, Ravicti, for treatment of urea cycle disorder - a rare but potentially deadly genetic disorder that affects the urea cycle - in patients aged two and older. The drug removes ammonia from the blood which can't be removed naturally in people with urea cycle disorders. Ammonia in the body can travel to the brain and cause brain damage. The drug is expected to be commercially available in April.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|